Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederjnj.com
RSS Feed ALL
Get the latest updates from RSS Feed ALL directly as they happen.
Follow now 204 followers
Latest posts
Last updated about 19 hours ago
Johnson & Johnson receives CHMP positive opinion for AKEEGA® (niraparib and abiraterone acetate dual action tablet) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) with BRCA1/2 mutations
about 19 hours ago
AMPLITUDE is the first clinical trial to evaluate potential therapies for patients...
DARZALEX FASPRO®-based quadruplet regimen approved in the U.S. for newly diagnosed patients with multiple myeloma who are transplant ineligible
4 days ago
Quadruplet regimen demonstrated significantly deeper and more durable responses, higher MRD negativity...
Johnson & Johnson Marks $100 Million of MedTech Products Donated Since 2020 to Help People Live, See and Smile
4 days ago
$20 million additional funding is planned for 2026 to support programs and...
Johnson & Johnson reports Q4 and Full-Year 2025 results
10 days ago
Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2024.
New clinical data highlights CAPLYTA® (lumateperone) as a promising option for achieving remission in adults with major depressive disorder
15 days ago
CAPLYTA® nearly doubled the likelihood of remission at six weeks compared to...
Johnson & Johnson Introduces Mobile Simulator App to Support Breast Augmentation Patients
16 days ago
The Arbrea Breast Simulator Surgeon App for Mentor provides real-time 3D simulations...
TECVAYLI® monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomide
17 days ago
TECVAYLI® alone reduced risk of disease progression or death by 71% in...
Johnson & Johnson elevates leadership in depression with new data at 2026 American College of Neuropsychopharmacology Annual Meeting
18 days ago
New CAPLYTA® (lumateperone) Phase 3 analyses evaluating efficacy in achieving remission in...
RYBREVANT® (amivantamab-vmjw) longer-term results show promising and durable responses in difficult-to-treat colorectal cancer
21 days ago
Over 70 percent of patients in the first-line subgroup responded to amivantamab...
Johnson & Johnson Reaches Agreement with U.S. Government to Improve Access to Medicines and Lower Costs for Millions of Americans; Delivers on U.S. Manufacturing and Innovation Investments
22 days ago
Voluntary agreement will allow millions of Americans to purchase medicines at significantly...
Johnson & Johnson celebrates innovation in cancer research with 2025 Dr. Paul Janssen Award
23 days ago
Tony Hunter, Ph.D., celebrated for pioneering discoveries that inspired the development of...
Johnson & Johnson Submits OTTAVA™ Robotic Surgical System to the U.S. Food and Drug Administration
24 days ago
Data from Investigational Device Exemption (IDE) study in Roux-en-Y gastric bypass procedures...